Skip to main content

COVID-19 Topic Center

Clinical Advances News

News Connection
Compared with electroconvulsive therapy, magnetic seizure therapy offered similar antidepressant efficacy but fewer cognitive side effects in patients with major depressive disorder (MDD), according to a study published in the Annals of Clinical Psychiatry.  The study is the first comparative…
Conference Insider
Findings from a retrospective study being presented at the 2019 ASH Annual Meeting support the use of bevacizumab to treat chronic bleeding and anemia in patients with hereditary hemorrhagic telangiectasia (HHT). “Bevacizumab…is a potential targeted anti-angiogenic treatment in HHT, which has no…
Conference Insider
Treatment of iron deficiency with low molecular weight iron dextran (LMWID) or ferumoxytol was well-tolerated and led to minimal adverse events (AEs), study findings have shown. “Iron deficiency anemia is the most common form of anemia and hematologic problem worldwide. Treatment options include…
Conference Insider
AK002—an anti-SIGLEC8 antibody—may be a safe and effective treatment option in eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE), according to results of ENIGMA, a phase 2 clinical trial. The findings were presented at the American College of Gastroenterology (ACG) 2019 Annual…
Conference Insider
Budesonide oral suspension (BOS) appears to be a safe and effective induction therapy for eosinophilic esophagitis (EoE) among adolescents and adults, according to results of a phase 3 clinical trial that were presented at the ACG 2019 Annual Scientific Meeting and Postgraduate Course. To assess…
Conference Insider
Results from a randomized phase 2 trial presented at the Society for Gynecologic Oncology’s 50th Annual Meeting show that a newly developed immunotherapy treatment combined with standard chemotherapy improve the prognosis for patients with recurrent ovarian cancer.  David Cibula, MD, PhD, of the…
Conference Insider
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.  The clinical trial, designed to monitor patients’ quality of…
Back to Top